Chief Medical Officer

Dr. Henig brings over 20 years of clinical and development leadership experience at biopharmaceutical companies, in combination with an extensive academic background in pulmonary and transplant medicine.

Prior to joining Breath Therapeutics in 2018, Dr. Henig served as Chief Development Officer of ProQR Therapeutics, where she oversaw preclinical and clinical development. Previously, she was Senior Director, Global Medical Affairs, Respiratory and PAH of Gilead Sciences, where she designed and executed clinical trials, up to Phase 4. Dr. Henig has also served as a member of the board of directors of Avidity Biosciences since August 2019.

Throughout her career, Dr. Henig held several senior academic positions in respiratory diseases and lung transplant at California Pacific Medical Center and Stanford University School of Medicine. She earned her M.D. with Distinction in Immunology from Albert Einstein College of Medicine, completed training in Internal Medicine at the University of California San Francisco and Pulmonary and Critical Care Medicine at the University of Washington.